Overview

Data as of September 18, 2020 08:37 pm EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Summary Toggle Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial

September 03, 2020

-- Completion of enrollment in MAESTRO-NAFLD-1 will enable reporting of topline 52-week data by the end of next year as planned. -- Madrigal intends to present selected data from ongoing open label arm by the end of 2020 -- Recent presentations at EASL Digital ILC of secondary analysis of Ph2 data
Summary Toggle Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020

August 26, 2020

CONSHOHOCKEN, Pa. , Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress ™ 2020, European Association for the Study of the Liver (EASL), secondary analyses of data from its Phase 2
Summary Toggle Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights

August 06, 2020

CONSHOHOCKEN, Pa. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and our CRO’s are focused on completing enrollment of both of our Phase 3 MAESTRO clinical trials as

Filing date	Form	Description	Filing Group	View
July 05, 2017	D		Other	0001288452-17-000002.rtf 0001288452-17-000002.pdf
December 12, 2019	424B7	424B7	Registration Statements	0001193125-19-312878.rtf 0001193125-19-312878.xls 0001193125-19-312878.pdf
April 17, 2013	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	0001047469-13-004491.rtf 0001047469-13-004491.xls 0001047469-13-004491.pdf